Clinical Trial Update: Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating SRA-333 in mild-to-moderate Alzheimer's disease has completed. The sponsor Wyeth is now a wholly owned subsidiary of Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SRA-333

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED